

David C Polidori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6428176/publications.pdf>

Version: 2024-02-01

37
papers

3,147
citations

236925

25
h-index

345221

36
g-index

38
all docs

38
docs citations

38
times ranked

3721
citing authors

#	ARTICLE	IF	CITATIONS
1	Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1232-1238.	8.6	372
2	Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, 2258-2265.	8.6	235
3	Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion. <i>Diabetes Care</i> , 2013, 36, 2154-2161.	8.6	234
4	Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 44-51.	3.6	212
5	Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models. <i>PLoS ONE</i> , 2012, 7, e30555.	2.5	193
6	Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport. <i>Diabetes Care</i> , 2015, 38, 2344-2353.	8.6	186
7	Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 601-610.	2.0	179
8	How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake. <i>Obesity</i> , 2016, 24, 2289-2295.	3.0	145
9	Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. <i>Diabetologia</i> , 2015, 58, 1183-1187.	6.3	118
10	Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 812-821.	4.4	117
11	Effect of canagliflozin on liver function tests in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2016, 42, 25-32.	2.9	107
12	Roux-en-Y Gastric Bypass Corrects Hyperinsulinemia Implications for the Remission of Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2525-2531.	3.6	104
13	Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. <i>Diabetologia</i> , 2014, 57, 891-901.	6.3	96
14	Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1027-1041.	3.5	83
15	Hepatic and Extrahepatic Insulin Clearance Are Differentially Regulated: Results From a Novel Model-Based Analysis of Intravenous Glucose Tolerance Data. <i>Diabetes</i> , 2016, 65, 1556-1564.	0.6	80
16	Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E867-E871.	3.6	77
17	Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. <i>Annals of the New York Academy of Sciences</i> , 2015, 1358, 28-43.	3.8	75
18	Hepatic but Not Extrahepatic Insulin Clearance Is Lower in African American Than in European American Women. <i>Diabetes</i> , 2017, 66, 2564-2570.	0.6	60

#	ARTICLE	IF	CITATIONS
19	Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes. <i>PLoS ONE</i> , 2014, 9, e105638.	2.5	53
20	Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1321-1326.	4.4	47
21	Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy Participants. <i>Clinical Therapeutics</i> , 2014, 36, 698-710.	2.5	46
22	Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1855-1865.	3.6	45
23	Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics. <i>Journal of Clinical Investigation</i> , 2020, 130, 3305-3314.	8.2	45
24	Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1296-1303.	3.4	43
25	Lower Insulin Clearance Parallels a Reduced Insulin Sensitivity in Obese Youths and Is Associated With a Decline in β -Cell Function Over Time. <i>Diabetes</i> , 2019, 68, 2074-2084.	0.6	30
26	Intrahepatic fat, irrespective of ethnicity, is associated with reduced endogenous insulin clearance and hepatic insulin resistance in obese youths: A cross-sectional and longitudinal study from the <sc>Y</sc>ale <sc>P</sc>ediatic <sc>NAFLD</sc> cohort. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1628-1638.	4.4	26
27	Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 676-687.	2.5	24
28	Effects of Meal Size on the Release of GLP-1 and PYY After Roux-en-Y Gastric Bypass Surgery in Obese Subjects With or Without Type 2 Diabetes. <i>Obesity Surgery</i> , 2014, 24, 1969-1974.	2.1	22
29	Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. <i>Clinical Therapeutics</i> , 2015, 37, 1483-1492.e1.	2.5	20
30	Dissection of hepatic versus extra-hepatic insulin clearance: Ethnic differences in childhood. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2869-2875.	4.4	20
31	Determination of the Renal Threshold for Glucose Excretion in Familial Renal Glucosuria. <i>Nephron</i> , 2015, 129, 300-304.	1.8	12
32	Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. <i>Clinical Therapeutics</i> , 2016, 38, 89-98.e1.	2.5	12
33	Optimal back-extrapolation method for estimating plasma volume in humans using the indocyanine green dilution method. <i>Theoretical Biology and Medical Modelling</i> , 2014, 11, 33.	2.1	11
34	Canagliflozin for the treatment of adults with Type 2 diabetes. <i>Diabetes Management</i> , 2015, 5, 183-201.	0.5	9
35	Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on C-peptide kinetics. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 12-17.	1.6	6
36	Quantitative path to deep phenotyping: Possible importance of reduced hepatic insulin degradation to type 2 diabetes mellitus pathogenesis. <i>Journal of Diabetes</i> , 2018, 10, 778-783.	1.8	3

#	ARTICLE	IF	CITATIONS
37	Response to Letter to the Editor: "Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content" Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5251-5252.	3.6	0